Table 1C.
Clinical characteristics, and follow-up after haplo-HSCT (MMRD) with and without HSV-TK gene transfer: patient and donor characteristics acute and chronic GvHD are summarized for two patients with HSV-TK T-cells and six control patients without gene transduced DLI.
| UPN | Age | Gender | DIAGN_PR | FAB- classification |
Status | HLA-donor | Source | Conditioning | GvHD_Proph | Acute GvHD | aGvHD-days | aGvHD_grade | ChrGvHD | CGvHD grade (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1505 | 23 | f | AML | M4/M5 | CR 1 | MMRD | PBPC | Flu/Mel ph/Thiotepa/ATG | TCD | Yes (post-DLI) | 131 | II | No | |
| 1550 | 25 | m | AML | MO | Induction failure | MMRD | KM+PBPC | Flamsa(TBI)/ATG | CSA/MTX | No | n.a. | Unknown | ||
| 1551 | 32 | f | AML | M5b | CR 2 | MMRD | PBPC | Flu/Mel ph/Thiotepa/ATG | TCD | No | n.a. | n.a. | ||
| 1438 | 34 | m | AML | M5b | CR 1 | MMRD | PBPC | Flu/Mel ph/Thiotepa/ATG | TCD | No | n.a. | No | ||
| 1269 | 18 | m | AML | M5a | CR 1 | MMRD | PBPC | Flu/Mel ph/Thiotepa/ATG | TCD | ja | 54 | I | Yes | |
| 1272 | 38 | m | AML | n.d. | CR 1 | MMRD | PBPC | Bu/Cy/ATG | CSA/MTX | No | n.a. | Yes | Limited (131) | |
| 1455 | 63 | m | AML | M2 | CR 2 | MMRD | PBPC | Flu/Mel ph/Thiotepa/ATG | TCD | No | n.a. | Yes | Limited (117) | |
| 1524 | 58 | f | AML | MO | CR 1 | MMRD | PBPC | Flamsa (w/o AMSA)(TBI)/ATG | CSA/MMF | ja | 30 | I | No |